MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.
MDxHealth is listed on the Euronext under the ticker symbol MDXH.
MDxHealth has been listed on Euronext since June 2006. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. There are no other financial instruments issued by the company other than stock options issued to employees, directors, and some consultants.
MDxHealth Corporate Presentation
MDxHealth Webcasts & Multimedia
January 26, 2016 CEO Jan Groen Ph.D. Bolero Interview